Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bio-K+
- Development stage
- Unknown
- Lead developer
- Bio-K+
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bio-K+ is a **probiotic combination** containing three specific strains: *Lactobacillus acidophilus* CL1285, *Lactobacillus casei* LBC80R, and *Lactobacillus rhamnosus* CLR2. This product has been **marketed in North America since 1996** for digestive health, especially the prevention of antibiotic-associated diarrhea and *Clostridioides difficile* (formerly *Clostridium difficile*) infection. Clinical studies demonstrate that Bio-K+ may reduce the incidence of antibiotic-associated diarrhea and *C. difficile* infection and improve symptoms of irritable bowel syndrome (IBS), especially diarrhea-predominant IBS. The mechanism of action involves colonization of the gut by these lactobacilli strains, competitive inhibition of pathogenic bacteria, production of lactic acid (which lowers intestinal pH and inhibits pathogens), direct antimicrobial activity, and possible toxin neutralization. The formulation is available in various forms including enteric-coated capsules and fermented beverages, and is considered to have a strong safety profile, with strains and products evaluated for identity, stability, and gastrointestinal survival[1][3][5][7].
- Brand names
- Bio-K+ IBS Control
- Other names
- lactobacillus acidophilus CL1285 + lactobacillus casei LBC80R + lactobacillus rhamnosus CLR2
Beyond the preview
Go deeper on Bio-K+.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bio-K+.